Opus Genetics, Inc.

NASDAQ:IRD

Biotechnology

Healthcare
$3.92 -0.12%

-$0.01 today

Market cap
$326.13M
Beta
0.55
P/E (TTM)
-33.0
EPS (TTM)
-$0.12
52W Low $0.90High $5.81

Volume 0.75M

Average 0.81M

IRD Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Opus Genetics, Inc.NASDAQ: IRD

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow growth accelerates

Q1 FY2026 free cash flow of $12.73M (cash outflow) rose 41.5% year over year, ahead of the +35.1% change in trailing-twelve-month free cash flow. Sequentially, it rose 29.4% from the prior quarter.

Context

  • Free cash flow amounted to 248.3% of revenue in FY2025, up 15.7 pp from a year earlier.
  • Free cash flow increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +41.5% holds above the trailing-twelve-month pace of +35.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.73M+29.4% QoQ
Last fiscal yearDec 2025
-$35.25M+37.8% YoY
LTMMar 2026
-$38.99M+35.1% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.5%——
1 year+37.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(35.25M) USD
Year-over-year change
-37.8%

Free Cash Flow vs competitors

How IRD compares with its peers on the latest reported figures

  • IRD's LTM Mar 2026 free cash flow of $38.99M is the 7th largest of the 10 companies compared; the peer median is $49.88M.
  • Its year-over-year change of +35.1% is the highest of 9, against a peer median of -25.3%.
  • Free cash flow amounts to 325.3% of revenue for IRD, versus a peer median of 636.1%.
IRD Competitors Peer median
Free Cash Flow for IRD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$173.2M -24.7%+96.0%940.4%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$105.55M +2.9%+48.5%—
AGENAgenus Inc.LTM Mar 2026$87.53M -40.2%-11.4%70.7%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$83.57M -18.6%-25.7%—
SEERSeer, Inc.LTM Mar 2026$49.88M -1.3%-13.3%331.7%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$42.37M -51.2%—3694.1%
IRDOpus Genetics, Inc.LTM Mar 2026$38.99M +35.1%—325.3%
TILInstil Bio, Inc.LTM Mar 2026$33.76M -25.8%-48.3%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$27.39M —+54.3%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$20.25M -34.9%+9.5%—
Peer median (excluding IRD) $49.88M-25.3%-0.9%636.1%

Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(56.69M)17.89M(9.99M)(57.53M)(49.59M)
Depreciation & Amortization4K4K6K10K53K
Deferred Income Tax00000
Stock-Based Compensation1.91M1.81M3.51M3.36M3.4M
Change in Working Capital181K(5.56M)4.08M3.09M(2.15M)
Accounts Receivables0(4.85M)2.52M(3.44M)2.61M
Inventory00000
Accounts Payables381K(515K)1.08M220K7K
Other Working Capital(200K)(190K)477K6.31M(4.77M)
Other Non-Cash Items35.22M170K1.28M25.49M13.04M
Operating Cash Flow(19.37M)14.31M(1.11M)(25.58M)(35.25M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(100K)001.21M0
Investing Cash Flow(100K)001.21M0
Debt Repayment538K(538K)001M
Common Stock Issued28.49M4.43M9.23M4.5M49.18M
Common Stock Repurchased000(79K)(152K)
Dividends Paid00000
Other Financing Activities(1.42M)(104K)(248K)(232K)0
Financing Cash Flow27.61M3.79M8.98M4.19M50.02M
Effect of Forex Changes00000
Net Change in Cash8.14M18.1M7.87M(20.18M)14.77M
Free Cash Flow(19.37M)14.31M(1.11M)(25.58M)(35.25M)

Opus Genetics, Inc.

NASDAQ:IRD

Intrinsic Alpha fair value

Locked

Current Price

$3.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.